SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS
申请人:Santhera Pharmaceuticals (Schweiz) AG
公开号:EP2240478A1
公开(公告)日:2010-10-20
[EN] SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE 4
申请人:SANTHERA PHARMACEUTICALS CH
公开号:WO2009080291A1
公开(公告)日:2009-07-02
The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression.
SmCp<sup>R</sup><sub>2</sub>-mediated cross-coupling of allyl and propargyl ethers with ketoesters and a telescoped approach to complex cycloheptanols
作者:Mateusz P. Plesniak、Xavier Just-Baringo、Fabrizio Ortu、David P. Mills、David J. Procter
DOI:10.1039/c6cc07318b
日期:——
A highly regio- and diastereoselective cross-coupling of allyl/propargylethers and [small beta]-ketoesters, mediated by SmCpR2 reagents, delivers decorated [small delta]-lactones. Screening of the Cp ligands on Sm(II) was employed to achieve high...